Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension

1995 ◽  
Vol 47 (6) ◽  
pp. 477-481 ◽  
Author(s):  
J. -M. Detry ◽  
◽  
P. Block ◽  
G. De Backer ◽  
J. -P. Degaute ◽  
...  
Keyword(s):  
Patient Compliance ◽  
Slow Release ◽  
Treatment Of Hypertension

Comparison of a Slow-Release Formulation of Oxprenolol with Conventional Oxprenolol in the Treatment of Hypertension

1976 ◽  
Vol 51 (s3) ◽  
pp. 559s-561s
Author(s):  
K. P. O'brien ◽  
E. J. W. Stephens
Keyword(s):  
Blood Pressure ◽  
Patient Compliance ◽  
Slow Release ◽  
Severe Hypertension ◽  
Total Daily Dose ◽  
Release Formulation ◽  
Once Daily ◽  
Slow Release Formulation ◽  
Daily Dose ◽  
Treatment Of Hypertension

1. Patients with moderate to severe hypertension were studied during a 12 weeks period, while taking a slow-release formulation of oxprenolol once daily, in a dose equal to their previous total daily dose of oxprenolol given in divided doses. 2. There were no significant differences between blood pressure at the beginning and end of the 12 weeks period. 3. Once-daily dosage offers advantages of patient compliance.

Effects of Metoprolol Administered as Conventional Tablets and as Slow-Release Tablets in the Treatment of Hypertension

1981 ◽  
Vol 3 (2) ◽  
pp. 406-408 ◽  
Author(s):  
Jakko Tuomilehto ◽  
Aulikki Nissinen
Keyword(s):  
Slow Release ◽  
Treatment Of Hypertension

Hemodynamic and Neurohumoral Effects of Nifedipine Slow-Release Tablet in the Treatment of Hypertension

1989 ◽  
pp. 109-118
Author(s):  
T. Santoso ◽  
D. Ismail ◽  
A. M. Rahman ◽  
M. N. T. Wangge ◽  
H. Mansjoer ◽  
...  
Keyword(s):  
Slow Release ◽  
Treatment Of Hypertension ◽  
Release Tablet

Blood Pressure Control – The Role of Single-pill Combination Therapies

2009 ◽  
Vol 5 (1) ◽  
pp. 52
Author(s):  
Michel Burnier ◽  
Keyword(s):  
Blood Pressure ◽  
Patient Compliance ◽  
Pressure Control ◽  
Combination Therapies ◽  
Poor Patient Compliance ◽  
Treatment Of Hypertension ◽  
Single Pill ◽  
Socioeconomic Burden ◽  
Event Rates

It is well-documented that reducing blood pressure (BP) in hypertensive individuals reduces the risk of cardiovascular events. Despite this, many patients with hypertension remain untreated or inadequately treated and fail to reach the recommended BP goals. Suboptimal BP control, while arising from multiple causes, is often due to poor patient compliance and/or persistence, and results in a significant healthcare and socioeconomic burden. By reducing the pill burden, the use of single-pill combination therapies for the treatment of hypertension has the potential to increase patient compliance and persistence. Compared with antihypertensive monotherapies, single-pill combinations may offer equivalent or better efficacy and the same or improved tolerability. As a result, single-pill combinations have the potential to reduce both the cardiovascular event rates and the non-drug healthcare costs associated with hypertension.

Patient Compliance and Therapeutic Coverage: Amlodipine versus Nifedipine (Slow-Release) in the Treatment of Angina Pectoris

1994 ◽  
Vol 22 (5) ◽  
pp. 278-286 ◽  
Author(s):  
J-M R Detry ◽  
P Block ◽  
G De Backer ◽  
J-P Degaute ◽  
R Six ◽  
...  
Keyword(s):  
Angina Pectoris ◽  
Monitoring System ◽  
Patient Compliance ◽  
Slow Release ◽  
Treatment Time ◽  
Electronic Device ◽  
Time Interval ◽  
Event Monitoring ◽  
Once Daily ◽  
Correct Dose

Patient compliance with therapy is often poor and overestimated by the treating physician; it is particularly important in cardiovascular diseases such as hypertension and angina pectoris. Compliance was studied in an open parallel study in out-patients with stable angina pectoris, given either amlodipine (5 mg, once daily) or slow-release nifedipine (20 mg, twice daily) for 12 weeks. Compliance was assessed using pill counting and using an electronic device, the medication event monitoring system, to record the time and date of each opening and closure of the pill container. There was no difference between the two groups in pill count or taking ‘in compliance’ (the percentage of prescribed doses taken as indicated by the monitoring system). Compliance was significantly better ( P < 0.001) with amlodipine, however, for ‘correct dosing’ (the percentage of days on which the correct dose was taken) and for ‘timing compliance’ (the percentage of doses taken at the prescribed time interval after the last dose). ‘Therapeutic coverage’ (the estimated proportion of treatment time for which the drug was active) was also significantly better for amlodipine ( P < 0.001). There was no difference in reported side-effects between the two therapies.

scholarly journals Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites

Pharmaceutics ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 82 ◽  
Author(s):  
Makoto Anraku ◽  
Ryo Tabuchi ◽  
Miwa Goto ◽  
Daisuke Iohara ◽  
Yasuyuki Mizukai ◽  
...  
Keyword(s):  
Sustained Release ◽  
Extended Release ◽  
Antihypertensive Effect ◽  
Slow Release ◽  
Solubility Method ◽  
Release Preparation ◽  
Treatment Of Hypertension ◽  
Sulfobutyl Ether

Sustained-release olmesartan tablets (OLM) were prepared by the simple, direct compression of composites of anionic sulfobutyl ether-β-cyclodextrin (SBE-β-CD) and cationic spray-dried chitosan (SD-CS), and were evaluated for use as a sustained release preparation for the treatment of hypertension. An investigation of the interaction between OLM and SBE-β-CD by the solubility method indicated that the phase diagram of the OLM/SBE-β-CD system was the AL type, indicating the formation of a 1:1 inclusion complex. The release of OLM from tablets composed of the SD-CS/SBE-β-CD composite was slow in media at both pH 1.2 and at 6.8. The in vitro slow release characteristics of the SD-CS/SBE-β-CD composite were reflected in the in vivo absorption of the drug after normal rats were given an oral administration of the preparation. Furthermore, the SD-CS/SBE-β-CD composite continuously increased the antihypertensive effect of OLM in hypertensive rats, compared with that of the drug itself. These results suggest that a simple mixing of SD-CS and SBE-β-CD can be potentially useful for the controlled release of a drug for the continuous treatments of hypertension.

Sign in / Sign up

Export Citation Format

Share Document